VAXIL COMMENCES PRECLINICAL COVID-19 VACCINE TRIAL AND FILES AN ADDITIONAL COVID-19 PATENT
Posted on March 27, 2020 by David Goren
?
27MAR
Not for distribution by US newswire or in United States
NESS-ZIONA, ISRAEL – March 27, 2020 – VAXIL BIO LTD. (“VAXIL” or the “COMPANY”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to provide an update of its COVID-19 research program and other updates.
COVID-19 VACCINE DEVELOPMENT
In February 2020 we announced that we believed that we had successfully identified a corona virus (COVID-19) vaccine candidate (“VACCINE CANDIDATE”). The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil’s proprietary VaxHitTM bioinformatics platform. The Vaccine Candidate is also based on successful in vivo experiments testing a tuberculosis signal peptide vaccine.
We are now pleased to announce that we have non-GMP vaccine material in hand and have begun to execute our preclinical program to test the efficacy of our COVID-19 vaccine candidate.
ADDITIONAL PATENT APPLICATION
In early March 2020, we announced our applications for a US patent (U.S 62/987,310) on a coronavirus vaccine intended to provide broad patent protection for novel vaccines, pharmaceutical compositions and methods of treating and preventing infectious disease as well as methods for producing a peptide vaccine against coronaviruses.
We are now also pleased to announce that today, Vaxil has applied for an additional patent in connection with COVID-19. An application for a US patent was filed on March 26, 2020 that is intended to provide coverage for a broader set of vaccine candidates.
